Beau R Webber

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4287375/publications.pdf

Version: 2024-02-01

29 papers	1,814 citations	471509 17 h-index	501196 28 g-index
37 all docs	37 docs citations	37 times ranked	2700 citing authors

#	Article	IF	Citations
1	EditR: A Method to Quantify Base Editing from Sanger Sequencing. CRISPR Journal, 2018, 1, 239-250.	2.9	304
2	TALEN-based Gene Correction for Epidermolysis Bullosa. Molecular Therapy, 2013, 21, 1151-1159.	8.2	232
3	Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Molecular Therapy, 2016, 24, 570-581.	8.2	168
4	Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature Communications, 2019, 10, 5222.	12.8	135
5	A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Molecular Therapy, 2020, 28, 52-63.	8.2	120
6	Fanconi Anemia Gene Editing by the CRISPR/Cas9 System. Human Gene Therapy, 2015, 26, 114-126.	2.7	94
7	Efficient targeted integration directed by short homology in zebrafish and mammalian cells. ELife, 2020, 9, .	6.0	93
8	Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood, 2011, 117, 839-847.	1.4	82
9	CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. Npj Regenerative Medicine, 2016, 1, .	5.2	74
10	Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments. Nature Communications, 2021, 12, 2815.	12.8	73
11	Base Editor Correction of COL7A1 in RecessiveÂDystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs. Journal of Investigative Dermatology, 2020, 140, 338-347.e5.	0.7	69
12	Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells. Blood, 2017, 129, 3428-3439.	1.4	56
13	Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease. Scientific Reports, 2018, 8, 12144.	3.3	55
14	CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells. Nature Communications, 2021, 12, 2437.	12.8	50
15	Rapid generation of Col7a1â^'/â^' mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells. Laboratory Investigation, 2017, 97, 1218-1224.	3.7	29
16	A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nature Communications, 2022, 13, 217.	12.8	27
17	CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. Stem Cells and Development, 2016, 25, 1591-1603.	2.1	24
18	CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. International Journal of Molecular Sciences, 2017, 18, 1269.	4.1	23

#	Article	IF	Citations
19	CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. International Journal of Molecular Sciences, 2018, 19, 946.	4.1	19
20	Comparative international incidence of Ewing sarcoma 1988 to 2012. International Journal of Cancer, 2021, 149, 1054-1066.	5.1	16
21	Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. Journal of Inherited Metabolic Disease, 2017, 40, 281-289.	3.6	12
22	From Marrow to Matrix: Novel Gene and Cell Therapies for Epidermolysis Bullosa. Molecular Therapy, 2015, 23, 987-992.	8.2	11
23	MultiEditR: The first tool for the detection and quantification of RNA editing from Sanger sequencing demonstrates comparable fidelity to RNA-seq. Molecular Therapy - Nucleic Acids, 2021, 25, 515-523.	5.1	11
24	Myosin Heavy Chain Converter Domain Mutations Drive Early-Stage Changes in Extracellular Matrix Dynamics in Hypertrophic Cardiomyopathy. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	8
25	Dermatopontin in Bone Marrow Extracellular Matrix Regulates Adherence but Is Dispensable for Murine Hematopoietic Cell Maintenance. Stem Cell Reports, 2017, 9, 770-778.	4.8	7
26	Genome Engineering of Primary Human B Cells Using CRISPR/Cas9. Journal of Visualized Experiments, 2020, , .	0.3	4
27	An irradiated marrow niche reveals a small non-collagenous protein mediator of homing, dermatopontin. Blood Advances, 2021, 5, 3609-3622.	5.2	2
28	Multiplex Human T Cell Engineering without Double-Strand Break Induction Using the Cas9 Base Editor System. Blood, 2018, 132, 3495-3495.	1.4	2
29	DNA Methylation Profile of Runx1 Regulatory Regions Is Correlated with Transition From Primitive to Definitive Hematopoietic Potential In Vitro and In Vivo. Blood, 2011, 118, 389-389.	1.4	0